Published Guideline
READ GUIDELINE
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer" originally published in the Journal for ImmunoTherapy of Cancer (JITC) on July 28, 2022 and has since been updated.
Updated Content (last reviewed 3/19/24)
SITC continually evaluates the field for practice-changing data and new FDA approvals that may affect the guideline. The information on this page provides a detailed overview of updates to the guideline content. Updates to the guideline outlined below were made with the approval of SITC's Breast Cancer CPG Expert Panel. More information on SITC Guidelines can be found
here.
v1.1 Update Summary
The FDA granted accelerated approval for retifanlimab (anti-PD-1 ICI) for the treatment of adult patients with metastatic or recurrent locally advanced MCC in March 2023. The NMSC CPG was updated in the following locations: Introduction, Merkel Cell Carcinoma, Recommended Immunotherapies for MCC, FDA-Approved ICI agents for NMSC, NMSC Landmark Clinical Trial Data Leading to FDA Approvals for ICIs for MCC, and Novel Stretegies and Promising Future Directions.
Data have been reported demonstrating efficacy with neoadjuvant anti-PD-1 ICI therapy prior to curative-intent surgery in patients with CSCC. Based on these practice-changing data, the NMSC CPG was updated in the following locations: Based on these practice-changing data, the NMSC CPG was updated in the following locations: Recommanded Immunotherapies for CSCC, and Novel Strategies and Promising Future Directions for CSCC.
Data have been reported demonstrating efficacy combining an anti-PD-(L)1 ICI with an anti-CTLA-4 ICI for patients with advanced MCC. Based on these practice-changing data, the NMSC CPG was updated in the following locations: Merkel Cell Carcinoma, Recommended Immunotherapies for MCC, and Novel Strategies and Future Directions for CSCC.